26.94
price down icon0.37%   -0.089
 
loading
Precedente Chiudi:
$27.03
Aprire:
$27.25
Volume 24 ore:
458.58K
Relative Volume:
0.26
Capitalizzazione di mercato:
$4.45B
Reddito:
$1.51B
Utile/perdita netta:
$333.35M
Rapporto P/E:
13.82
EPS:
1.95
Flusso di cassa netto:
$315.22M
1 W Prestazione:
-7.77%
1M Prestazione:
-7.96%
6M Prestazione:
-15.18%
1 anno Prestazione:
+7.72%
Intervallo 1D:
Value
$26.68
$27.27
Intervallo di 1 settimana:
Value
$26.05
$29.74
Portata 52W:
Value
$25.56
$36.45

Alkermes Plc Stock (ALKS) Company Profile

Name
Nome
Alkermes Plc
Name
Telefono
00-353-1-772-8000
Name
Indirizzo
CONNAUGHT HOUSE, DUBLIN 4
Name
Dipendente
1,800
Name
Cinguettio
@alkermes
Name
Prossima data di guadagno
2024-10-24
Name
Ultimi documenti SEC
Name
ALKS's Discussions on Twitter

Confronta ALKS con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - Specialty & Generic icon
ALKS
Alkermes Plc
26.96 4.76B 1.51B 333.35M 315.22M 1.95
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
151.92 68.05B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.77 46.58B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.755 43.71B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.52 18.40B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
303.03 13.23B 2.99B 1.21B 1.13B 25.06

Alkermes Plc Stock (ALKS) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-07-15 Iniziato Goldman Buy
2025-06-17 Aggiornamento UBS Neutral → Buy
2025-05-28 Iniziato Needham Buy
2025-03-13 Iniziato RBC Capital Mkts Sector Perform
2025-03-04 Aggiornamento UBS Sell → Neutral
2025-02-11 Iniziato Deutsche Bank Buy
2024-11-05 Aggiornamento Stifel Hold → Buy
2024-06-17 Iniziato TD Cowen Buy
2024-03-19 Iniziato Robert W. Baird Outperform
2024-02-20 Downgrade UBS Neutral → Sell
2023-11-20 Ripresa JP Morgan Neutral
2023-10-24 Aggiornamento Evercore ISI In-line → Outperform
2023-10-17 Iniziato UBS Neutral
2022-11-03 Aggiornamento Piper Sandler Neutral → Overweight
2022-10-14 Aggiornamento BofA Securities Underperform → Neutral
2022-08-16 Iniziato Piper Sandler Neutral
2022-04-22 Ripresa Goldman Buy
2022-04-20 Iniziato Goldman Buy
2022-01-27 Aggiornamento Cantor Fitzgerald Hold → Overweight
2021-12-01 Iniziato Citigroup Neutral
2021-10-07 Aggiornamento Jefferies Hold → Buy
2021-09-02 Downgrade BofA Securities Neutral → Underperform
2020-10-15 Aggiornamento Mizuho Neutral → Buy
2020-07-30 Downgrade Goldman Neutral → Sell
2020-02-14 Downgrade BofA/Merrill Buy → Neutral
2020-02-14 Reiterato H.C. Wainwright Neutral
2020-02-14 Downgrade JP Morgan Overweight → Neutral
2020-02-06 Iniziato Mizuho Neutral
2020-01-31 Aggiornamento Wolfe Research Underperform → Peer Perform
2019-09-05 Aggiornamento Morgan Stanley Underweight → Equal-Weight
2019-07-15 Aggiornamento Goldman Sell → Neutral
2019-05-31 Iniziato H.C. Wainwright Neutral
2019-05-01 Downgrade Citigroup Buy → Neutral
2018-12-19 Downgrade Goldman Neutral → Sell
2018-12-14 Iniziato Wolfe Research Underperform
2018-12-13 Downgrade Credit Suisse Outperform → Underperform
2018-11-05 Iniziato Piper Jaffray Neutral
2018-08-07 Iniziato Stifel Hold
2018-06-21 Downgrade Morgan Stanley Equal-Weight → Underweight
2018-06-06 Iniziato B. Riley FBR, Inc. Buy
2018-05-16 Aggiornamento Citigroup Neutral → Buy
2018-05-11 Iniziato BofA/Merrill Buy
Mostra tutto

Alkermes Plc Borsa (ALKS) Ultime notizie

pulisher
05:48 AM

Alkermes plc Stock Analysis and ForecastSuperior investment outcomes - jammulinksnews.com

05:48 AM
pulisher
04:49 AM

What analysts say about Alkermes plc stockSuperior trading gains - Autocar Professional

04:49 AM
pulisher
03:00 AM

What drives Alkermes plc stock priceConsistently exceptional gains - Autocar Professional

03:00 AM
pulisher
Jul 22, 2025

Is Alkermes plc a good long term investmentFree Wealth Planning Blueprint - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Alkermes (ALKS) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance

Jul 22, 2025
pulisher
Jul 22, 2025

ALKS Down Despite Positive Top-Line Data From Narcolepsy Study - TradingView

Jul 22, 2025
pulisher
Jul 22, 2025

Alkermes plc (NASDAQ:ALKS) Launches Phase II Trial of ALKS 2680 for Idiopathic Hypersomnia - MSN

Jul 22, 2025
pulisher
Jul 21, 2025

Alkermes Announces Positive Phase 2 Study Results - TipRanks

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results - insights.citeline.com

Jul 21, 2025
pulisher
Jul 21, 2025

Jefferies Raises Target for Alkermes (ALKS) Following Promising Drug Data | ALKS Stock News - GuruFocus

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives. - inkl

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes Oral Drug Helps Patients Stay Awake In Mid-Stage Sleep Disorder Study - inkl

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes narcolepsy drug headed for late-stage testing - BioPharma Dive

Jul 21, 2025
pulisher
Jul 21, 2025

Needham & Company LLC Reaffirms Buy Rating for Alkermes (NASDAQ:ALKS) - MarketBeat

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes stock rating reiterated as Buy by Stifel after positive narcolepsy data - Investing.com UK

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes Vibrance-1 Phase 2 Study Of Alixorexton In Narcolepsy Type 1 Meets Primary Goal - Nasdaq

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes announces positive topline results from Vibrance-1 Phase 2 study - MarketScreener

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes narcolepsy drug shows positive results in phase 2 trial By Investing.com - Investing.com UK

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1 - PR Newswire

Jul 21, 2025
pulisher
Jul 20, 2025

Is Alkermes Plc's (NASDAQ:ALKS) Latest Stock Performance Being Led By Its Strong Fundamentals? - 富途牛牛

Jul 20, 2025
pulisher
Jul 19, 2025

10 Most Undervalued Pharma Stocks To Buy Now - Insider Monkey

Jul 19, 2025
pulisher
Jul 18, 2025

Goldman Sachs Initiates Alkermes (ALKS) with a Buy Rating - MSN

Jul 18, 2025
pulisher
Jul 17, 2025

BlackRock increases stake in Alkermes to 17.05% By Investing.com - Investing.com India

Jul 17, 2025
pulisher
Jul 17, 2025

BlackRock increases stake in Alkermes to 17.05% - Investing.com

Jul 17, 2025
pulisher
Jul 15, 2025

Alkermes to Release Q2 Financial Results on July 29, 2025 - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

Alkermes to Report Second Quarter Financial Results on July 29, 2025 - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

Expert Outlook: Alkermes Through The Eyes Of 6 Analysts - Benzinga

Jul 15, 2025
pulisher
Jul 15, 2025

Goldman Sachs Initiates Coverage on Alkermes (ALKS) with a Buy R - GuruFocus

Jul 15, 2025
pulisher
Jul 14, 2025

How Much Upside is Left in Alkermes (ALKS)? Wall Street Analysts Think 33.19% - Yahoo Finance

Jul 14, 2025
pulisher
Jul 14, 2025

(ALKS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

Jul 14, 2025
pulisher
Jul 08, 2025

Alkermes (NASDAQ:ALKS) shareholders have earned a 9.3% CAGR over the last five years - simplywall.st

Jul 08, 2025
pulisher
Jul 03, 2025

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Alkermes plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 22, 2018ALKS - ACCESS Newswire

Jul 03, 2025
pulisher
Jul 03, 2025

Zacks Industry Outlook Highlights Exelixis, Verona Pharma, Alkermes, Kiniska Pharmaceuticals and Immunocore - Yahoo Finance

Jul 03, 2025
pulisher
Jun 30, 2025

Alkermes plc(NasdaqGS: ALKS) added to Russell 2500 Value Index - MarketScreener

Jun 30, 2025
pulisher
Jun 26, 2025

Alkermes spinoff Mural plunges on plans to halt ovarian cancer trial - MSN

Jun 26, 2025
pulisher
Jun 23, 2025

(ALKS) On The My Stocks Page - news.stocktradersdaily.com

Jun 23, 2025
pulisher
Jun 18, 2025

Alkermes Gains Momentum With Promising Narcolepsy Drug - Finimize

Jun 18, 2025
pulisher
Jun 18, 2025

Alkermes (ALKS) Upgraded by UBS with Positive Development Prospe - GuruFocus

Jun 18, 2025
pulisher
Jun 17, 2025

Alkermes stock upgraded at UBS on sleep disorder drug (ALKS) - Seeking Alpha

Jun 17, 2025

Alkermes Plc Azioni (ALKS) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Alkermes Plc Azioni (ALKS) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Nichols Christian Todd
SVP, Chief Commercial Officer
Jun 10 '25
Sale
31.09
3,334
103,654
86,208
$72.99
price up icon 1.09%
$15.11
price up icon 1.21%
$9.37
price up icon 1.46%
drug_manufacturers_specialty_generic RDY
$14.79
price up icon 2.60%
$133.50
price up icon 0.60%
$302.96
price up icon 1.59%
Capitalizzazione:     |  Volume (24 ore):